Literature DB >> 31290170

Hospice utilization among Medicare beneficiaries dying from pancreatic cancer.

Anghela Z Paredes1,2, J Madison Hyer1,2, Diamantis I Tsilimigras1,2, Rittal Mehta1,2, Kota Sahara1,2, Susan White1,2, Mary E Dillhoff1,2, Aslam Ejaz1,2, Jordan M Cloyd1,2, Timothy M Pawlik1,2.   

Abstract

BACKGROUND: Use of hospice services among patients with pancreatic cancer following pancreatic resection remains unknown.
METHODS: Patients with pancreatic cancer who underwent resection were identified in the Medicare Standard Analytic Files. Outcomes included overall hospice use, early hospice enrollment (≥4 weeks before death), late hospice enrollment (initiation within 3 days of death), and Medicare expenditures.
RESULTS: Among the 4369 deceased individuals, three-fourths of patients (n = 3252, 74.4%) used hospice at the time of death. Patients who did not use hospice were more likely to be male, have a complication on index admission and receive life sustaining treatments on subsequent admissions (P < .05). Only one-third (32.2%) of patients initiated hospice services early. Medicare expenditure during the last month of life was $10 000 lower among patients who initialized hospice services at least 1 month before death versus within 3 days of death (late: $10 581 [$5454-$17 200], early: $221 [$46-$733]; P < .001)
CONCLUSION: While three-fourths of patients utilized hospice services after pancreatic resection, only one-third of patients initiated hospice services at least one-month before death. Late hospice use was associated with higher Medicare expenditures during the last month of life. Further research is needed to understand barriers to early hospice utilization.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Medicare; hospice; pancreatic cancer

Mesh:

Year:  2019        PMID: 31290170     DOI: 10.1002/jso.25623

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  End-of-Life Hospice Use and Medicare Expenditures Among Patients Dying of Hepatocellular Carcinoma.

Authors:  Daniel R Rice; J Madison Hyer; Adrian Diaz; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2021-02-02       Impact factor: 5.344

Review 2.  Systematic review of the predictors of health service use in pancreatic cancer.

Authors:  Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

3.  Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer.

Authors:  Anghela Z Paredes; J Madison Hyer; Elizabeth Palmer; Maryam B Lustberg; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2020-03-19       Impact factor: 3.452

Review 4.  Immunotherapy Versus Hospice: Treatment Decision-Making in the Modern Era of Novel Cancer Therapies.

Authors:  Amy An; David Hui
Journal:  Curr Oncol Rep       Date:  2022-02-03       Impact factor: 5.075

5.  Characteristics and Procedures Among Adults Discharged to Hospice After Gastrointestinal Tract Surgery in California.

Authors:  Anya L Greenberg; Joseph A Lin; Alexis Colley; Emily Finlayson; Tasce Bongiovanni; Elizabeth C Wick
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  Emergency Department Utilization Following Hepatopancreatic Surgery Among Medicare Beneficiaries.

Authors:  Alessandro Paro; Djhenne Dalmacy; J Madison Hyer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-06-18       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.